$240B Market

In partnership with

The Key to This $240B Market Is in Your Bloodstream

Every year, $240B is spent on treating the symptoms of osteoarthritis. But not a single therapy has been able to actually stop it. The answer, it turns out, has been inside us all along.

A startup named Cytonics discovered the human body already produces a protein designed to protect cartilage. It just doesn’t produce enough where it's needed most. So Cytonics harnessed it. 

Their first-generation therapy has already treated 10,000+ patients. Now they've engineered a 200% more potent, mass-producible version pushing toward FDA approval.

If approved, it could be the first therapy to actually halt cartilage destruction and promote regrowth in a market that has never had a real solution. Claim a piece at the pre-clinical stage as an early-stage investor before March 26 to receive time-sensitive investor bonuses.

Invest in Cytonics Now

^{This is a paid advertisement for Cytonics Regulation CF offering. Please read the offering circular at https://cytonics.com/}